BRPI0514035A - composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto - Google Patents
composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um compostoInfo
- Publication number
- BRPI0514035A BRPI0514035A BRPI0514035-8A BRPI0514035A BRPI0514035A BR PI0514035 A BRPI0514035 A BR PI0514035A BR PI0514035 A BRPI0514035 A BR PI0514035A BR PI0514035 A BRPI0514035 A BR PI0514035A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- depression
- therapy
- enantiomers
- mixtures
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000020401 Depressive disease Diseases 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0401971A SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Piperidne derivatives |
| PCT/SE2005/001189 WO2006014136A1 (en) | 2004-08-02 | 2005-07-27 | Piperidine derivatives as histamine h3 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0514035A true BRPI0514035A (pt) | 2008-05-27 |
Family
ID=32906883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514035-8A BRPI0514035A (pt) | 2004-08-02 | 2005-07-27 | composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080064706A1 (enExample) |
| EP (1) | EP1781613A1 (enExample) |
| JP (1) | JP2008508353A (enExample) |
| KR (1) | KR20070043998A (enExample) |
| CN (1) | CN1993325A (enExample) |
| AU (1) | AU2005267932A1 (enExample) |
| BR (1) | BRPI0514035A (enExample) |
| CA (1) | CA2576112A1 (enExample) |
| IL (1) | IL180548A0 (enExample) |
| MX (1) | MX2007001226A (enExample) |
| RU (1) | RU2007105970A (enExample) |
| SE (1) | SE0401971D0 (enExample) |
| WO (1) | WO2006014136A1 (enExample) |
| ZA (1) | ZA200700683B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026844A1 (en) | 2003-04-03 | 2005-02-03 | Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| JP2007532484A (ja) | 2004-03-16 | 2007-11-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法 |
| EP1814875A4 (en) | 2004-10-20 | 2010-02-17 | Univ California | IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE |
| ES2639621T3 (es) | 2004-12-30 | 2017-10-27 | Janssen Pharmaceutica N.V. | Derivados de fenilamida del ácido 4-(bencil)-piperazina-1-carboxílico y compuestos relacionados como moduladores de la amida hidrolasa de ácidos grasos (FAAH) para el tratamiento de la ansiedad, el dolor y otras afecciones |
| EP1909797A4 (en) | 2005-08-02 | 2013-02-27 | Neurogen Corp | DIPIPERAZINYL KETONE AND RELATED ANALOG |
| TW200808723A (en) * | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
| AU2008267895A1 (en) * | 2007-06-22 | 2008-12-31 | F. Hoffmann-La Roche Ag | Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors |
| US7888354B2 (en) | 2007-11-13 | 2011-02-15 | Taisho Pharmaceutical Co., Ltd | Phenylpyrazole derivatives |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010068452A1 (en) * | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
| CN104193761B (zh) | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| US9045445B2 (en) | 2010-06-04 | 2015-06-02 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| AR088256A1 (es) | 2011-10-08 | 2014-05-21 | Novartis Ag | Derivados de carbamato / urea como antagonistas del receptor h3 |
| EP2789608A4 (en) | 2011-12-08 | 2015-07-01 | Taisho Pharmaceutical Co Ltd | PHENYLPYRROLDERIVAT |
| WO2013100054A1 (ja) | 2011-12-27 | 2013-07-04 | 大正製薬株式会社 | フェニルトリアゾール誘導体 |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
| TWI703130B (zh) | 2014-03-07 | 2020-09-01 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
| CA2949511A1 (en) * | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
| EP3383853B1 (en) | 2015-12-01 | 2020-11-04 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease |
| KR102640774B1 (ko) | 2016-03-22 | 2024-02-26 | 헬신 헬쓰케어 에스.에이. | 벤젠술포닐-비대칭 우레아 및 그의 의학적 용도 |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| US11077090B2 (en) | 2016-07-29 | 2021-08-03 | Sunovion Pharmaceuticals Inc. | Compounds and compositions and uses thereof |
| EA201990400A1 (ru) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | Соединения и композиции и их применение |
| SI3571193T1 (sl) | 2017-01-23 | 2022-04-29 | Cadent Therapeutics, Inc. | Modulatorji kalijevega kanalčka |
| CN110678205B (zh) | 2017-02-16 | 2023-05-23 | 桑诺维恩药品公司 | 治疗精神分裂症的方法 |
| CA3070993C (en) | 2017-08-02 | 2025-05-20 | Sunovion Pharmaceuticals Inc | ISOCHROMANE COMPOUNDS AND THEIR USES |
| US10815249B2 (en) | 2018-02-16 | 2020-10-27 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
| MY208662A (en) | 2018-04-18 | 2025-05-22 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2019226491A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2020086456A1 (en) | 2018-10-22 | 2020-04-30 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
| CN111349609A (zh) * | 2018-12-21 | 2020-06-30 | 泰州医药城国科化物生物医药科技有限公司 | 一种无标记组胺受体h3的细胞筛选模型 |
| KR20210139376A (ko) | 2019-03-14 | 2021-11-22 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물 |
| EP3969444A4 (en) * | 2019-05-13 | 2023-10-18 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS |
| ES2819309B2 (es) * | 2019-10-14 | 2021-11-17 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas |
| CA3180115A1 (en) | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
| CN113549006B (zh) * | 2020-04-26 | 2023-07-21 | 江苏恩华药业股份有限公司 | 一种酰胺衍生物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0343307A1 (en) * | 1988-05-26 | 1989-11-29 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. | 4-Piperidinealkanamine derivatives |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6673829B2 (en) * | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
| DE60234616D1 (de) * | 2001-09-14 | 2010-01-14 | High Point Pharmaceuticals Llc | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren |
| US7064135B2 (en) * | 2001-10-12 | 2006-06-20 | Novo Nordisk Inc. | Substituted piperidines |
| US20060052597A1 (en) * | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
| US7332508B2 (en) * | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| EP1669350B1 (en) * | 2003-09-22 | 2012-02-29 | Msd K.K. | Piperidine derivatives |
-
2004
- 2004-08-02 SE SE0401971A patent/SE0401971D0/xx unknown
-
2005
- 2005-07-27 WO PCT/SE2005/001189 patent/WO2006014136A1/en not_active Ceased
- 2005-07-27 MX MX2007001226A patent/MX2007001226A/es not_active Application Discontinuation
- 2005-07-27 CN CNA2005800262732A patent/CN1993325A/zh active Pending
- 2005-07-27 BR BRPI0514035-8A patent/BRPI0514035A/pt not_active Application Discontinuation
- 2005-07-27 RU RU2007105970/04A patent/RU2007105970A/ru not_active Application Discontinuation
- 2005-07-27 CA CA002576112A patent/CA2576112A1/en not_active Abandoned
- 2005-07-27 KR KR1020077002643A patent/KR20070043998A/ko not_active Withdrawn
- 2005-07-27 AU AU2005267932A patent/AU2005267932A1/en not_active Abandoned
- 2005-07-27 EP EP05761797A patent/EP1781613A1/en not_active Withdrawn
- 2005-07-27 JP JP2007524768A patent/JP2008508353A/ja not_active Abandoned
- 2005-07-27 US US11/572,967 patent/US20080064706A1/en not_active Abandoned
-
2007
- 2007-01-04 IL IL180548A patent/IL180548A0/en unknown
- 2007-01-24 ZA ZA200700683A patent/ZA200700683B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1993325A (zh) | 2007-07-04 |
| EP1781613A1 (en) | 2007-05-09 |
| CA2576112A1 (en) | 2006-02-09 |
| US20080064706A1 (en) | 2008-03-13 |
| JP2008508353A (ja) | 2008-03-21 |
| MX2007001226A (es) | 2007-03-23 |
| SE0401971D0 (sv) | 2004-08-02 |
| WO2006014136A1 (en) | 2006-02-09 |
| AU2005267932A1 (en) | 2006-02-09 |
| RU2007105970A (ru) | 2008-09-10 |
| KR20070043998A (ko) | 2007-04-26 |
| IL180548A0 (en) | 2007-06-03 |
| ZA200700683B (en) | 2008-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0514035A (pt) | composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto | |
| BRPI0514032A (pt) | composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto | |
| BRPI0510599A (pt) | compostos, processo para a preparação dos mesmos, composição farmacêutica, uso de um composto, e método para o tratamento e a profilaxia de doenças | |
| BRPI0414330A (pt) | composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| BR0313160A (pt) | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| BRPI0410563B8 (pt) | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas | |
| BRPI0511532A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto | |
| BRPI0517634A (pt) | derivado de tiazol ou um derivado farmaceuticamente aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BRPI0508540A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
| BRPI0512796A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença | |
| BRPI0414780A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia da dor em um animal de sangue quente, e para preparar um composto | |
| BRPI0514036A (pt) | composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto | |
| BRPI0511531A (pt) | composto, uso de um composto, composição farmacêutica, e, métodos para terapia de distúrbios gastrointestinais funcionais, de sìndrome do intestino irritável e de distúrbio de refluxo gastro-esofágico e para preparar um composto | |
| BRPI0514679A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| BRPI0411246A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para terapia contra dor em um animal de sangue quente e para a preparação de um composto | |
| BR0315320A (pt) | Composto ou sais farmaceuticamente aceitáveis dos mesmos, uso de um composto, composição farmacêutica, e, métodos para a terapia de dor em um animal de sangue quente e para produzir um composto | |
| BRPI0513513A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente | |
| BRPI0515860A (pt) | derivados de tetralin e indano, e uso dos mesmos | |
| BRPI0411226A (pt) | composto, uso de um composto, composição farmacêutica, e, método para a terapia contra dor em um animal de sangue quente, e para a preparação de um composto | |
| BR0315995A (pt) | Composto, uso de um composto composição farmacêutica, métodos para a terapia da dor, de distúrbios gastrointestinais, e da ansiedade em um animal de sangue quente, e, processo para preparar um composto | |
| BR0315998A (pt) | Composto, uso de mesmo, composição farmacêutica, métodos para a terapia da dor e de distúrbios gastrointestinais funcionais em um animal de sangue quente, e, processo para preparar um composto | |
| BRPI0406614A (pt) | Composto, uso do mesmo, composição farmacêutica, métodos para a terapia de dor em um animal de sangue quente e para a terapia de distúrbios gastrointestinais funcionais em um animal de sangue quente, e, processo para preparar um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |